Pacira BioSciences
PCRX
239 hedge funds and large institutions have $1.24B invested in Pacira BioSciences in 2025 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 67 increasing their positions, 95 reducing their positions, and 30 closing their positions.
374% more call options, than puts
Call options by funds: $3.13M | Put options by funds: $661K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 30
3% more funds holding
Funds holding: 233 → 239 (+6)
2% more capital invested
Capital invested by funds: $1.21B → $1.24B (+$28.4M)
2.41% less ownership
Funds ownership: 109.17% → 106.76% (-2.4%)
29% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 95
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DPCM
Doma Perpetual Capital Management
Miami,
Florida
|
+$22M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$4.81M |
| 4 |
Morgan Stanley
New York
|
+$4.73M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$21.8M |
| 2 |
BlackRock
New York
|
-$11.3M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.9M |
| 4 |
Millennium Management
New York
|
-$10.9M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$8.16M |
PCRX Hedge Fund Activity: Q3 2025 in Review
239 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2025, worth a combined $1.24B — up 2.3% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PCRX positions and 30 closed out — a net gain of 7 holders — while 67 added to existing stakes and 95 trimmed.
The largest buyer was Doma Perpetual Capital Management, adding an estimated $22M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $21.8M sold.
- 239 institutional investors held Pacira BioSciences (PCRX) as of Q3 2025, up from 233 in Q2 2025.
- Funds reported $1.24B of Pacira BioSciences stock for Q3 2025, up 2.3% quarter-over-quarter.
- 37 funds opened new Pacira BioSciences positions in Q3 2025 and 30 closed out, a net change of +7 holders.
- The largest Pacira BioSciences buyer in Q3 2025 was Doma Perpetual Capital Management, an estimated $22M added.
- The largest Pacira BioSciences seller in Q3 2025 was Polar Capital Holdings, an estimated $21.8M sold.
Based on aggregated 13F filings for Q3 2025.